How to Conduct On-Site Capability Audits for Clinical Trial Sites

Introduction: The Role of On-Site Capability Audits

Before initiating a clinical trial at an investigator site, sponsors and CROs must assess whether the site is operationally ready and compliant with GCP and regulatory expectations. While feasibility questionnaires and remote assessments are important, on-site capability audits—also known as pre-study visits (PSVs) or site qualification visits—provide a firsthand evaluation of infrastructure, documentation, staffing, SOPs, and past performance. These audits are critical to ensuring that selected sites can execute the protocol safely, efficiently, and in accordance with local and international regulations.

Conducting thorough on-site capability audits reduces the risk of protocol deviations, delays in startup, and inspection findings during the trial. This article provides a complete, step-by-step framework for conducting these audits, including audit scope, checklist items, documentation requirements, and post-audit follow-up.

1. Objectives of On-Site Capability Audits

The primary goals of a site capability audit include:

• Verifying information provided in feasibility questionnaires
• Assessing infrastructure, staff availability, and training
• Reviewing essential SOPs, equipment, and document control
• Evaluating regulatory preparedness and EC/IRB interaction history
• Determining readiness for sponsor systems (EDC, IRT, eTMF, etc.)
• Documenting findings to support site selection or exclusion

These audits also provide an opportunity to build early rapport with the site and identify training needs prior to site initiation.

2. Pre-Audit Planning and Logistics

Effective site audits begin with comprehensive planning. Sponsors and CROs should:

• Define the audit objectives (e.g., protocol-specific, general readiness)
• Send a formal visit notification to the site with agenda and documents required
• Assign qualified clinical research associates (CRAs) or site auditors
• Develop an audit plan and checklist tailored to the trial type
• Confirm availability of key personnel (PI, study coordinator, lab, pharmacy)

Sites should be instructed to prepare relevant documentation, equipment records, SOP binders, and training logs for review during the audit.

3. Key Audit Areas and Checklist Elements

During the visit, auditors should systematically review the following areas:

3.1. Investigator and Staff Qualifications

• Review of PI and sub-investigator CVs (signed and dated)
• GCP training certificates (within 2 years)
• Organizational chart and staff roles
• Delegation of Duties Log (DOL) – if available

3.2. Infrastructure and Facility Tour

• Dedicated clinical space for patient visits and informed consent
• Secure IP storage (restricted access, temperature monitoring)
• -20°C and -80°C freezer availability with backup power
• Exam room, ECG, phlebotomy, and lab capabilities
• Document archiving areas (fireproof cabinets, access control)

3.3. Equipment and Calibration Records

• Equipment inventory list
• Calibration certificates (within 12 months)
• Preventive maintenance logs
• Service contracts or vendor support details

3.4. SOPs and Quality Systems

• SOP binder with current version-controlled SOPs
• Procedures for IP handling, AE/SAE reporting, source documentation, deviations
• Training logs for SOPs and protocol-specific instructions
• Process for SOP revision and staff notification

3.5. Regulatory and Ethics Committee Documentation

• Past EC/IRB approval letters
• Average approval timelines and submission procedures
• Meeting schedules and submission calendars
• Site regulatory binder availability and completeness

3.6. Technology Readiness

• Internet connectivity and speed test
• Availability of computers with secure access to EDC/IRT
• eConsent capability, if applicable
• Remote monitoring or source upload options

Example Facility Readiness Table:

4. Conducting Interviews with Site Personnel

Auditors should engage with key site staff to assess preparedness, workload, and understanding of their roles. Interviews should include:

• Principal Investigator – oversight strategy, GCP familiarity, competing studies
• Study Coordinator – protocol knowledge, source documentation process
• Pharmacist – IP accountability, temperature excursion handling
• Lab Staff – sample processing, lab manual access, kit inventory management

Interview responses should be documented in the audit report and compared against SOPs and feasibility responses.

5. Documentation and Reporting

Upon completing the audit, the auditor must issue a formal Site Qualification Visit (SQV) report or Audit Report that includes:

• Visit date, location, protocol, and auditor name
• Summary of findings by audit section
• Photographic evidence (if permitted)
• Corrective actions or clarifications required
• Recommendation: Select / Do Not Select / Conditional Approval

The report should be reviewed and approved by sponsor QA or feasibility leads, and stored in the Trial Master File (TMF) under the site qualification section.

6. Post-Audit Follow-Up and Decision Making

If findings are noted, the site should be asked to provide responses or evidence of corrective action before final selection. For example:

• Missing calibration certificates → Submit within 10 business days
• Inadequate GCP training → Staff to complete training within 7 days
• Protocol deviations in prior trial → Submit CAPA plan

Once corrective actions are received and accepted, a final decision on site activation can be made. Conditional approvals should be documented with date-bound resolutions.

7. Regulatory and Inspection Considerations

Regulatory agencies may request audit reports or documentation justifying site selection. Inspectors often review:

• Audit plans and SOPs used for site qualification
• Site qualification reports and follow-up correspondence
• Feasibility data and verification during on-site audit
• Consistency between audit findings and TMF documentation

According to ICH E6(R2), sponsors are responsible for ensuring that sites are qualified and capable before starting any trial-related activities.

8. Best Practices for On-Site Capability Audits

• Use standardized audit checklists across all studies and regions
• Train auditors on protocol-specific risks and critical elements
• Document everything with dates, names, and source references
• Involve quality assurance for high-risk or rescue site audits
• Use digital audit tools (e.g., Veeva Vault, eQMS platforms) for traceability

Conclusion

On-site capability audits are vital to ensuring that clinical trial sites are prepared, qualified, and compliant with GCP and regulatory standards. They provide the most accurate insight into a site’s operational maturity and highlight risks that may not be visible through questionnaires alone. By implementing structured audit frameworks, using comprehensive checklists, and engaging with site teams directly, sponsors can make informed, inspection-ready decisions that support successful trial execution from the start.

How to Assess PI and Staff Availability During Clinical Trial Feasibility

One of the most critical yet often overlooked components of site feasibility is evaluating the availability of the Principal Investigator (PI) and supporting staff. A well-equipped site can still underperform if key personnel are stretched thin or unavailable during critical study phases. Ensuring dedicated and timely involvement from the PI and site team during feasibility reduces risks, improves data quality, and keeps your trial on schedule. This article explains how to assess staff and PI availability during the feasibility stage.

Why PI and Staff Availability Matters

Site success is driven not just by infrastructure or patient availability but also by the people running the study. Inadequate staff time allocation can lead to:

• Delayed protocol compliance and patient enrollment
• Missed assessments or visits
• Data entry backlogs and query delays
• Poor communication with CRAs and sponsors

Therefore, understanding the day-to-day bandwidth of the PI and the study team is vital for feasibility decision-making.

Key Roles to Evaluate During Feasibility

1. Principal Investigator (PI): Must provide oversight, conduct informed consent, and ensure protocol adherence.
2. Sub-Investigators: Support the PI in clinical assessments and subject monitoring.
3. Study Coordinator: Handles scheduling, visit logistics, and EDC entry.
4. Pharmacist: Responsible for Investigational Product (IP) storage and accountability.
5. Data Entry Staff: Maintains eCRF entries and responds to data queries.

Questions to Include in Feasibility Forms

Include targeted queries in your feasibility questionnaire to gauge real-world availability:

• “How many trials is the PI currently overseeing?”
• “Will the PI be present during all SIV and first patient visits?”
• “What are the backup arrangements for the PI?”
• “List ongoing trials with estimated time commitments.”
• “Do you foresee any planned leave or sabbaticals during the study period?”

These responses help determine whether a site is overburdened or capable of taking on a new trial.

Conducting PI Interviews

Beyond forms, personal interviews (virtual or in-person) with the PI offer critical insights. During these, assess:

• Understanding of the protocol and enthusiasm for the study
• History of protocol compliance and inspection outcomes
• Whether the PI has blocked time in their calendar for subject visits and AE reviews
• Communication approach with site staff and CRAs

Record responses in a centralized Pharma SOP checklist for internal documentation.

Evaluating Support Staff Availability

Aside from the PI, staff availability is critical for seamless operations. Look into:

• Ratio of full-time coordinators per trial
• Availability of trained backup coordinators or data entry personnel
• Dedicated pharmacy and lab personnel for sample handling and IP dispensing
• Training records and certifications as per GMP guidelines

Red Flags to Watch For

• PI involved in more than 5 concurrent trials without sub-I support
• Unplanned or frequent PI absences in historical trials
• High turnover rate in study staff
• Shared staff across departments without trial prioritization
• Lack of clarity about who will perform study procedures

Documenting Availability in CTMS

Capture availability metrics in your Clinical Trial Management System (CTMS) such as:

• PI % allocation to this study
• Average daily availability of study coordinators
• Scheduled training sessions for protocol-specific tasks
• Planned absences or institutional leaves

Using a PI and Staff Readiness Scorecard

Create a weighted scorecard during feasibility assessment with parameters such as:

• PI commitment (30%)
• Staff-to-study ratio (25%)
• Historical compliance (20%)
• Contingency planning (15%)
• Protocol understanding (10%)

This scorecard ensures objective comparison between candidate sites.

Regulatory Expectations

As per USFDA and ICH GCP (E6 R2) guidance, the PI must maintain overall responsibility for trial conduct. Sites must demonstrate adequate human resources at the time of feasibility. Audit findings often cite PI absenteeism or lack of oversight as major issues in trial quality.

Conclusion

Assessing PI and staff availability is a fundamental pillar of feasibility assessment. Sponsors must ensure that key personnel are not only qualified but also sufficiently available to maintain protocol compliance and patient safety. A structured approach—through interviews, checklists, and scorecards—helps quantify availability and minimize trial delays.